Showing results (91-100 of 128) with videos related to
Sort By:
Pageof 13
Nature Medicine|February 28, 2012
Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALLGiusy Della Gatta, Teresa Palomero, Arianne Perez-Garcia, et al.Cancer Discovery|October 29, 2021
Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic LeukemiaMarissa Rashkovan, Robert Albero, Francesca Gianni, et al.Proceedings of the National Academy of Sciences of the United States of America|August 27, 2009
Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cellsStephen J Salipante, Matthew E Mealiffe, Jeremy Wechsler, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2006
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responsesCharles H Redfern, Troy H Guthrie, Alberto Bessudo, et al.Blood|December 1, 2007
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)Anthony H Goldstone, Susan M Richards, Hillard M Lazarus, et al.Blood|February 27, 2009
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993Adele K Fielding, Jacob M Rowe, Susan M Richards, et al.British Journal of Haematology|March 29, 2020
At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trialChezi Ganzel, Xin V Wang, Jacob M Rowe, et al.Acta Haematologica|September 16, 2016
Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic LeukemiaMuhamed Baljevic, Bogdan Dumitriu, Ju-Whei Lee, et al.Blood|December 16, 2006
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trialAnthony V Moorman, Christine J Harrison, Georgina A N Buck, et al.Pageof 13